Phase 2 N=64 A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
Parkinson's Disease
Primary: Maintenance Dose of the SPM962 — 0; 0; 0; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=156 Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
Urinary Bladder, Overactive
Primary: Change From Baseline in the Daily Average Number of Micturition (Urination) Episodes — 13.7; 12.2; 11.0; 10.6 Episodes
Phase 2 N=174 A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients
Parkinson's Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score — -10.1; -4.4 Scores on a scale
Phase 2 N=102 Open-label Study of Safety and Tolerability of Memantine in Children With Autism
Autism · Pediatric Autism
Primary: Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE) — 85 participants
Phase 2 N=29 Clofarabine Bone Marrow Cytoreduction
Leukemia
Primary: Cytoreductive Response — 52 percentage of participants
Phase 2 N=57 Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Phase 2 N=74 A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4 — -37.9; -65.7; -38.1; -12.0 mg/dL — p=<0.001
Phase 2 N=148 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
Systemic Sclerosis · Scleroderma
Primary: Net Ulcer Burden — 1.0; 2.0; 0.0; -1.0 ulcers — p=0.20
Phase 2 N=37 Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function
Heart Failure · Asymptomatic Systolic Dysfunction
Primary: Change in Urinary Sodium Excretion in Response to Saline Load — 179.1; 3.1 mEq/min — p=<0.05
Phase 2 N=51 Naltrexone in the Treatment of Trichotillomania
Trichotillomania
Primary: National Institute of Mental Health Trichotillomania Symptom Severity Scale — 7.94; 8.73 units on a scale
Phase 2 N=15 Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma
Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)
Phase 2 N=65 Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
Epilepsies, Partial
Primary: Number of Treatment-Emergent Adverse Events (AEs) by Severity: Double-blind Treatment — 0; 2; 2; 4 adverse events
Phase 2 N=48 Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
Breast Cancer
Primary: Clinical Response Rate — 47 Participants
Phase 2 N=126 Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
Ischemic Stroke · Stroke · Brain Infarction
Primary: Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset — 3; 2; 22; 99 participants — p=0.053
Phase 2 N=21 Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Celecoxib Combined With Radiation Therapy (RT) — 0; 1 units on a scale